Survival of Malnourished Head and Neck Cancer Patients Can Be Predicted by Human Leukocyte Antigen-DR Expression and Interleukin-6/Tumor Necrosis Factor-α Response of the Monocyte-Reference-Cited by-同舟云学术

Survival of Malnourished Head and Neck Cancer Patients Can Be Predicted by Human Leukocyte Antigen-DR Expression and Interleukin-6/Tumor Necrosis Factor-α Response of the Monocyte

Published:2000-11 Issue:6 Volume:24 Page:329-336
ISSN:0148-6071
Container-title:Journal of Parenteral and Enteral Nutrition
language:en
Short-container-title:JPEN J Parenter Enteral Nutr

Author:

van Bokhorst-de van der Schueren Marian A. E.,von Blomberg-van der Flier B. Mary E.,Kuik Dirk J.,Scholten Petra E. T.,Siroen Michiel P. C.,Snow Gordon B.,Quak Jasper J.,van Leeuwen Paul A. M.

Publisher

Wiley

Subject

Nutrition and Dietetics,Medicine (miscellaneous)

Reference39 articles.

1. Assessment of malnutrition parameters in head and neck cancer and their relation to postoperative complications

2. The impact of nutritional status on the prognoses of patients with advanced head and neck cancer

3. Differences in immune status between well-nourished andmalnourished head and neck cancer patients

4. Monocyte HLA-DR antigen expression characterizes clinical outcome in the trauma patient

5. Monocyte expression of class II antigens

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Developing symptom-specific dietary leaflets to address radiotherapy side effects using an eDelphi method;Radiography;2024-03

2. Associations Between Diet Quality and Proinflammatory Cytokines in Newly Diagnosed Head and Neck Cancer Survivors;Current Developments in Nutrition;2023-11

3. Protocol for the SEHNeCa randomised clinical trial assesing Supervised Exercise for Head and Neck Cancer patients;BMC Cancer;2023-03-24

4. Evaluation of sarcopenia as a prognostic biomarker in locally advanced head and neck squamous cell carcinoma;Biomarkers in Medicine;2023-01

5. The association between body mass index and efficacy of pembrolizumab as second‐line therapy in patients with recurrent/metastatic head and neck squamous cell carcinoma;Cancer Medicine;2022-08-17